<DOC>
	<DOC>NCT02090621</DOC>
	<brief_summary>The purpose of this study is to determine the safety of photopheresis for prophylaxis of allograft rejection in patients who are being withdrawal immunosuppression after liver transplantation.</brief_summary>
	<brief_title>Extracorporeal Photopheresis After Liver Transplant</brief_title>
	<detailed_description>The photopheresis (ECP) is a therapeutic approach based on the biological effect of ultraviolet light A on mononuclear cells collected by apheresis, and reinfused into the patient.</detailed_description>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Liver transplantation 2 years ago &gt;18 years Treatment with immunosuppression (Cyclosporine or tacrolimus) Normal hepatic function during last year No acute or chronic rejection to have some secondary effect because of immunosuppressors Previous disease: alcoholic liver cirrhosis with or without hepatocarcinoma, metabolic disease, amyloid polyneuropathy, hepatitis,cryptogenic cirrhosis and non autoimmune causes Signing consent informed form Additional liver Transplantation hypersensitivity to methoxsalen Patients with melanoma ,cutaneous carcinoma Patients with aphakia Patients treated with oxsoralen Pregnant women, lactating women or fertile adults that they donÂ´t use a effective anticonception method Involved in other assay.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Liver</keyword>
	<keyword>transplantation</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>photopheresis</keyword>
	<keyword>extracorporeal</keyword>
</DOC>